LTRN Lantern Pharma Inc.
Nasdaq · SEC CIK 1763950 · EDGAR
- Bought, last 12 months
- $200.0K 2 purchases by 2 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 52 since 2021-11-02, latest 2026-05-14 16:10
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Schalop Lee Troy | Dir | $100.0K | — |
| KEYSER D JEFFREY | Dir | $100.0K | — |
Transactions 26
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-14 16:10 | 2026-05-12 | LTRN | Schalop Lee Troy | Dir | P - Purchase | $2.06 | +48.5K | 48.5K | New | +$100.0K |
| D | 2026-05-14 16:10 | 2026-05-12 | LTRN | KEYSER D JEFFREY | Dir | P - Purchase | $2.06 | +48.5K | 94.3K | +106% | +$100.0K |
| MI | 2025-06-13 | 2025-06-10+ | LTRN | Cavu Advisors, LLC | 10% | S - Sale | $3.38 | -61.6K | 51.9K | -54% | -$208.3K |
| MI | 2025-06-13 | 2025-06-13 | LTRN | BIOS Fund II QP, LP | 10% | S - Sale | $3.09 | -40.0K | 189.1K | -17% | -$123.6K |
| MI | 2025-06-13 | 2025-06-10+ | LTRN | BIOS Fund I, LP | 10% | S - Sale | $3.38 | -61.6K | 354.3K | -15% | -$208.3K |
| MI | 2025-06-13 | 2025-06-13 | LTRN | BP Directors, LP | 10% | S - Sale | $3.09 | -40.0K | 189.1K | -17% | -$123.6K |
| MI | 2025-05-29 | 2025-05-27+ | LTRN | Cavu Advisors, LLC | 10% | S - Sale | $2.99 | -56.2K | 56.5K | -50% | -$168.4K |
| MI | 2025-05-29 | 2025-05-27+ | LTRN | BIOS Advisors GP, LLC | 10% | S - Sale | $2.99 | -56.2K | 127.5K | -31% | -$168.4K |
| D | 2024-07-26 | 2024-07-24 | LTRN | KEYSER D JEFFREY | Dir | X - OptEx | $3.13 | +3,832 | 0 | New | +$12.0K |
| MI | 2024-05-28 | 2024-05-23+ | LTRN | Cavu Advisors, LLC | 10% | S - Sale | $6.30 | -30.0K | 59.3K | -34% | -$189.1K |
| MI | 2024-05-28 | 2024-05-23+ | LTRN | Fletcher Aaron G.L. | 10% | S - Sale | $6.30 | -30.0K | 57.5K | -34% | -$189.1K |
| MI | 2024-02-29 | 2024-02-27+ | LTRN | Bios Equity Partners II, LP | 10% | S - Sale | $4.70 | -144.0K | 515.4K | -22% | -$676.3K |
| MI | 2024-02-29 | 2024-02-27+ | LTRN | BP Directors, LP | 10% | S - Sale | $4.70 | -144.0K | 463.8K | -24% | -$676.3K |
| DMI | 2024-01-19 | 2024-01-17 | LTRN | BIOS Fund I, LP | 10% | S - Sale+OE | $4.20 | -58.9K | 73.6K | -44% | -$247.3K |
| DMI | 2024-01-19 | 2024-01-17 | LTRN | BIOS Fund I, LP | 10% | X - OptEx | $3.13 | +79.0K | 180.9K | +78% | +$247.3K |
| DMI | 2024-01-19 | 2024-01-17 | LTRN | BP Directors, LP | 10% | X - OptEx | $3.13 | +79.0K | 591.0K | +15% | +$247.3K |
| DMI | 2024-01-19 | 2024-01-17 | LTRN | BP Directors, LP | 10% | S - Sale+OE | $4.20 | -58.9K | 550.1K | -10% | -$247.3K |
| MI | 2023-12-01 | 2023-11-29 | LTRN | Cavu Management, LP | 10% | S - Sale | $3.44 | -145.3K | 371.9K | -28% | -$500.0K |
| MI | 2023-12-01 | 2023-11-29 | LTRN | Fletcher Aaron G.L. | 10% | S - Sale | $3.44 | -145.3K | 371.9K | -28% | -$500.0K |
| MI | 2022-11-09 | 2022-11-08 | LTRN | BIOS Fund I, LP | 10% | S - Sale | $4.40 | -350.0K | 71.8K | -83% | -$1.54M |
| MI | 2022-11-09 | 2022-11-08 | LTRN | Cavu Management, LP | 10% | S - Sale | $4.40 | -350.0K | 463.7K | -43% | -$1.54M |
| DMI | 2022-09-07 | 2022-09-02 | LTRN | BP Directors, LP | 10% | X - OptEx | $1.03 | +32.5K | 27.3K | New | +$33.5K |
| DMI | 2022-09-07 | 2022-09-02 | LTRN | BP Directors, LP | 10% | S - Sale+OE | $5.20 | -6,445 | 26.1K | -20% | -$33.5K |
| DMI | 2022-09-07 | 2022-09-02 | LTRN | BIOS Fund II, LP | 10% | X - OptEx | $1.03 | +32.5K | 26.1K | New | +$33.5K |
| DMI | 2022-09-07 | 2022-09-02 | LTRN | BIOS Fund II, LP | 10% | S - Sale+OE | $5.20 | -6,445 | 20.9K | -24% | -$33.5K |
| DMI | 2022-03-21 | 2022-03-17 | LTRN | Fletcher Aaron G.L. | 10% | X - OptEx | $160,176.01 | +95.8K | 564.0K | +20% | +$15.34B |
Purchase Sale Sale after option exercise All abbreviations